WO2026080688A1 - Conjugués anticorps-médicament à charge utile à double mécanisme d'action - Google Patents

Conjugués anticorps-médicament à charge utile à double mécanisme d'action

Info

Publication number
WO2026080688A1
WO2026080688A1 PCT/US2025/050211 US2025050211W WO2026080688A1 WO 2026080688 A1 WO2026080688 A1 WO 2026080688A1 US 2025050211 W US2025050211 W US 2025050211W WO 2026080688 A1 WO2026080688 A1 WO 2026080688A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
antibody conjugate
antibody
independently
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/050211
Other languages
English (en)
Inventor
Samer DAHER
Krishna Mohan BAJJURI
Daniel Calarese
Alice Yam
Gang Yin
Helena KIEFEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sutro Biopharma Inc
Original Assignee
Sutro Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc filed Critical Sutro Biopharma Inc
Publication of WO2026080688A1 publication Critical patent/WO2026080688A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des conjugués anticorps-médicament à charge utile à double mécanisme d'action comprenant au moins deux résidus de charge utile, des compositions pharmaceutiques de ceux-ci, et l'utilisation des conjugués anticorps-médicament et de leurs compositions pour le traitement de maladies et de troubles, notamment les maladies prolifératives.
PCT/US2025/050211 2024-10-09 2025-10-09 Conjugués anticorps-médicament à charge utile à double mécanisme d'action Pending WO2026080688A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463705298P 2024-10-09 2024-10-09
US63/705,298 2024-10-09
US202563805680P 2025-05-14 2025-05-14
US63/805,680 2025-05-14

Publications (1)

Publication Number Publication Date
WO2026080688A1 true WO2026080688A1 (fr) 2026-04-16

Family

ID=97751231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/050211 Pending WO2026080688A1 (fr) 2024-10-09 2025-10-09 Conjugués anticorps-médicament à charge utile à double mécanisme d'action

Country Status (1)

Country Link
WO (1) WO2026080688A1 (fr)

Citations (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1993021259A1 (fr) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Macromolecules dendritiques et leur procede de production
WO1995020045A1 (fr) 1994-01-21 1995-07-27 The Institute Of Cancer Research: Royal Cancer Hospital Anticorps contre le recepteur d'egf et leur effet antitumeur
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
WO1996021469A1 (fr) 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Derives multibras monofonctionnels et stables du point de vue hydrolitique de poly(ethylene glycol), et polymeres apparentes pourla modification de surfaces et de molecules
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
WO1996040210A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5589369A (en) 1992-02-11 1996-12-31 Cell Genesys Inc. Cells homozygous for disrupted target loci
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5677171A (en) 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5891996A (en) 1972-09-17 1999-04-06 Centro De Inmunologia Molecular Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
WO2000034337A1 (fr) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Anticorps monoclonaux humanises luttant contre un facteur de croissance de cellules endotheliales vasculaires
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
WO2001062931A2 (fr) 2000-02-25 2001-08-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services SCFV ANTI-EGFRvIII POSSEDANT UNE CYTOTOXICITE ET UN RENDEMENT AMELIORES, IMMUNOTOXINES A BASE DE CES SCFV ET PROCEDE D'UTILISATION ASSOCIE
WO2001088138A1 (fr) 2000-05-19 2001-11-22 Scancell Limited Anticorps humanises contre le recepteur du facteur de croissance epidermique
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
WO2002085923A2 (fr) 2001-04-19 2002-10-31 The Scripps Research Institute Incorporation in vivo d'acides amines non naturels
US20030143596A1 (en) 2001-11-07 2003-07-31 Shearwater Corporation Branched polymers and their conjugates
EP1444268A2 (fr) 2001-11-12 2004-08-11 Gundram Jung Molecule d'anticorps anti-cd28 bispecifique
WO2005111082A1 (fr) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps anti-tfr
US7247301B2 (en) 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8258082B2 (en) 2000-12-18 2012-09-04 Dyax Corp. Focused libraries of genetic packages
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20130189287A1 (en) 2011-12-23 2013-07-25 Paul Scherrer Institut Enzymatic conjugation of polypeptides
US20130251783A1 (en) 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
WO2013185115A1 (fr) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8703936B2 (en) 2010-02-12 2014-04-22 The Regents Of The University Of California Compositions and methods for modification of biomolecules
WO2015006555A2 (fr) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
US9145361B2 (en) 2011-03-25 2015-09-29 Life Technologies Corporation SDP-containing heterobifunctional agents
US9222940B2 (en) 2010-04-27 2015-12-29 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
WO2016123582A1 (fr) 2015-01-30 2016-08-04 Sutro Biopharma, Inc. Dérivés d'hémiasterline pour conjugaison et thérapie
US10596270B2 (en) 2017-09-18 2020-03-24 Sutro Biopharma, Inc. Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
US20200129639A1 (en) * 2016-12-14 2020-04-30 Seattle Genetics, Inc. Multi-drug antibody drug conjugates
WO2020252015A1 (fr) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. Conjugués anticorps-médicament immunomodulateurs et utilisations associées
WO2023249473A1 (fr) * 2022-06-24 2023-12-28 주식회사 피노바이오 Conjugué anticorps-médicament avec deux types de conjugués médicament-lieur sur un anticorps unique
US20240108744A1 (en) * 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2025064427A1 (fr) * 2023-09-18 2025-03-27 R.P. Scherer Technologies, Llc Conjugués anticorps-médicament à double charge utile et leurs utilisations
WO2025080711A1 (fr) * 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Conjugués médicament-anticorps à double charge utile
WO2025083071A2 (fr) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Conjugués anticorps-médicament
WO2025083069A1 (fr) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Molécules de liaison à her2

Patent Citations (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891996A (en) 1972-09-17 1999-04-06 Centro De Inmunologia Molecular Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4618492A (en) 1984-08-29 1986-10-21 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5677171A (en) 1988-01-12 1997-10-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5591669A (en) 1988-12-05 1997-01-07 Genpharm International, Inc. Transgenic mice depleted in a mature lymphocytic cell-type
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5589369A (en) 1992-02-11 1996-12-31 Cell Genesys Inc. Cells homozygous for disrupted target loci
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993021259A1 (fr) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Macromolecules dendritiques et leur procede de production
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1995020045A1 (fr) 1994-01-21 1995-07-27 The Institute Of Cancer Research: Royal Cancer Hospital Anticorps contre le recepteur d'egf et leur effet antitumeur
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6506883B2 (en) 1994-11-18 2003-01-14 Centro De Inmunologia Molecular Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996021469A1 (fr) 1995-01-10 1996-07-18 Shearwater Polymers, Inc. Derives multibras monofonctionnels et stables du point de vue hydrolitique de poly(ethylene glycol), et polymeres apparentes pourla modification de surfaces et de molecules
WO1996040210A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
WO2000034337A1 (fr) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Anticorps monoclonaux humanises luttant contre un facteur de croissance de cellules endotheliales vasculaires
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
WO2001062931A2 (fr) 2000-02-25 2001-08-30 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services SCFV ANTI-EGFRvIII POSSEDANT UNE CYTOTOXICITE ET UN RENDEMENT AMELIORES, IMMUNOTOXINES A BASE DE CES SCFV ET PROCEDE D'UTILISATION ASSOCIE
WO2001088138A1 (fr) 2000-05-19 2001-11-22 Scancell Limited Anticorps humanises contre le recepteur du facteur de croissance epidermique
US8258082B2 (en) 2000-12-18 2012-09-04 Dyax Corp. Focused libraries of genetic packages
US20030108885A1 (en) 2001-04-19 2003-06-12 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs
US20030082575A1 (en) 2001-04-19 2003-05-01 The Scripps Research Institute In vivo incorporation of unnatural amino acids
WO2002085923A2 (fr) 2001-04-19 2002-10-31 The Scripps Research Institute Incorporation in vivo d'acides amines non naturels
US7247301B2 (en) 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20030143596A1 (en) 2001-11-07 2003-07-31 Shearwater Corporation Branched polymers and their conjugates
EP1444268A2 (fr) 2001-11-12 2004-08-11 Gundram Jung Molecule d'anticorps anti-cd28 bispecifique
US7375078B2 (en) 2004-02-23 2008-05-20 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005111082A1 (fr) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps anti-tfr
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8703936B2 (en) 2010-02-12 2014-04-22 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US9222940B2 (en) 2010-04-27 2015-12-29 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
US9145361B2 (en) 2011-03-25 2015-09-29 Life Technologies Corporation SDP-containing heterobifunctional agents
US20130251783A1 (en) 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
US20130189287A1 (en) 2011-12-23 2013-07-25 Paul Scherrer Institut Enzymatic conjugation of polypeptides
US20140356385A1 (en) 2011-12-23 2014-12-04 Innate Pharma Enzymatic conjugation of antibodies
WO2013185115A1 (fr) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
WO2015006555A2 (fr) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
WO2016123582A1 (fr) 2015-01-30 2016-08-04 Sutro Biopharma, Inc. Dérivés d'hémiasterline pour conjugaison et thérapie
US20200129639A1 (en) * 2016-12-14 2020-04-30 Seattle Genetics, Inc. Multi-drug antibody drug conjugates
US10596270B2 (en) 2017-09-18 2020-03-24 Sutro Biopharma, Inc. Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
WO2020252015A1 (fr) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. Conjugués anticorps-médicament immunomodulateurs et utilisations associées
WO2023249473A1 (fr) * 2022-06-24 2023-12-28 주식회사 피노바이오 Conjugué anticorps-médicament avec deux types de conjugués médicament-lieur sur un anticorps unique
US20240108744A1 (en) * 2022-07-27 2024-04-04 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2025064427A1 (fr) * 2023-09-18 2025-03-27 R.P. Scherer Technologies, Llc Conjugués anticorps-médicament à double charge utile et leurs utilisations
WO2025080711A1 (fr) * 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Conjugués médicament-anticorps à double charge utile
WO2025083071A2 (fr) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Conjugués anticorps-médicament
WO2025083069A1 (fr) * 2023-10-16 2025-04-24 Hummingbird Bioscience Pte. Ltd. Molécules de liaison à her2

Non-Patent Citations (88)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 2009
ABHINANDANMARTIN, IMMUNOLOGY, vol. 45, 2008, pages 3832 - 3839
AL-LAZIKANI ET AL., J. MOL. BIOL., vol. 273, 1997, pages 927 - 948
AMSBERRY ET AL., J. ORG. CHEM., vol. 55, 1990, pages 5867
AZOULAY, M., VILMONT, M., FRAPPIER, F.: "Glutamine analogues as Potential Antimalarials", EUR. J. MED. CHEM., vol. 26, 1991, pages 201 - 5
BARBAS ET AL., PROC. NAT. ACAD. SCI. U.S.A., vol. 91, 1994, pages 3809 - 3813
BARNES ET AL., ANAL. BIOCHEM., vol. 102, 1980, pages 255
BARTON: "Synthesis of Novel a-Amino-Acids and Derivatives Using Radical Chemistry: Synthesis of L- and D-a-Amino-Adipic Acids, L-a-aminopimelic Acid and Appropriate Unsaturated Derivatives", TETRAHEDRON LETT., vol. 43, 1987, pages 4297 - 4308
BRUGGERMANN ET AL., YEAR IN IMMUNO, vol. 7, 1993, pages 33
CAREYSUNDBERG: "Advanced Organic Chemistry", 1990, WILEY AND SONS
CHIN J ET AL., SCIENCE, vol. 301, 2003, pages 964 - 7
CHIN, J. W ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 9026 - 9027
CHRISTIE, B. DRAPOPORT, H: "Synthesis of Optically Pure Pipecolates from L-Asparagine. Application to the Total Synthesis of (+)-Apovincamine through Amino Acid Decarbonylation and Iminium Ion Cyclization", J. ORG. CHEM. 1989, 1985, pages 1859 - 1866
CORNISH, V. W. ET AL., J. AM. CHEM. SOC, vol. 118, 1996, pages 8150 - 8151
CRAIG, J. C ET AL.: "Absolute Configuration of the Enantiomers of 7-Chloro-4 [[4-(diethylamino)-1-methylbutyl]amino]quinoline (Chloroquine", J. ORG. CHEM., vol. 53, 1988, pages 1167 - 1170
DEITERS, A ET AL., J. AM. CHEM. SOC., vol. 125, 2003, pages 11782 - 11783
E. SAXONC. BERTOZZI, SCIENCE, vol. 287, 2000, pages 2007 - 2010
FANGER, M W ET AL., CRIT REV IMMUNOL, vol. 12, no. 34, 1992, pages 101 - 24
FOSTER ET AL., ADV. DRUG RES, vol. 14, 1985, pages 1 - 36
FRIEDMAN, O. MCHATTERRJI, R: "Synthesis of Derivatives of Glutamine as Model Substrates for Anti-Tumor Agents", J. AM. CHEM. SOC, vol. 81, 1959, pages 3750 - 3752
GATELY ET AL., J. NUCL. MED, vol. 27, 1986, pages 388
GEOGHEGAN, K. FSTROH, J. G, BIOCONJUG. CHEM, vol. 3, 1992, pages 138 - 146
GORDON ET AL., DRUG METAB. DISPOS, vol. 15, 1987, pages 589
GUSS ET AL., EMBO J., vol. 5, 1986, pages 1567 - 1575
H. HANGC. BERTOZZI, ACC. CHEM. RES, vol. 34, 2001, pages 727 - 736
HAM ET AL., METH. ENZ, vol. 58, no. 44, 1979
HAMANN ET AL., EXPERT OPIN. THER. PATENTS, vol. 15, no. 2005, 2005, pages 1087 - 1103
HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
HAY ET AL., BIOORG. MED. CHEM. LETT, vol. 9, 1999, pages 2237
HONEGGEPLUCKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 70
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
JACKSON ET AL., J. IMMUNOL., vol. 154, 1995, pages 3310 - 33199
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 2551
JENCKS, W. P., J. AM. CHEM. SOC., vol. 81, 1959, pages 475 - 481
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JUNGBLUTH, PROC. NATL. ACAD. SCI. USA, vol. 100, no. 2, 2003, pages 639 - 44
KAYSER, B ET AL., TETRAHEDRON, vol. 53, no. 7, 1997, pages 2475 - 2484
KETTLEBOROUGH ET AL., PROTEIN ENG, vol. 4, no. 7, 1991, pages 773 - 83
KIICK ET AL.: "Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation", PNAS, vol. 99, 2002, pages 19 - 24
KING, F. EKIDD, D. A. A: "J. Chem. Soc", 1949, article "A New Synthesis of Glutamine and of -Dipeptides of Glutamic Acid from Phthylated Intermediates", pages: 3315 - 3319
KING, MWAGNER, A: "Developments in the Field of Bioorthogonal Bond Forming Reactions - Past and Present Trends", BIOCONJUGATE CHEM., 2014, vol. 25, no. 5, 2014, pages 825 - 839
KINGSBURY, J. MED. CHEM., vol. 27, 1984, pages 1447
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495 - 497
KOSKINEN, A. M. PRAPOPORT, H.: "Synthesis of 4-Substituted Prolines as Conformationally Constrained Amino Acid Analogues", J. ORG. CHEM, vol. 54, 1989, pages 1859 - 1866
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001 - 176
KUSHNER ET AL., CAN. J. PHYSIOL. PHARMACOL, vol. 77, 1999, pages 79 - 88
LANG, KCHIN, J: "Bioorthogonal Reactions for Labeling Proteins", ACS CHEM BIOL, vol. 9, 2014, pages 16 - 20
LEFRANC ET AL., DEV. COMP. IMMUNOL, vol. 27, 2003, pages 55 - 77
LIJINSKY ET AL., FOOD COSMET. TOXICOL, vol. 20, 1982, pages 393
LIJINSKY ET AL., J. NAT. CANCER INST, vol. 69, 1982, pages 1127 - 161
LINDMARK ET AL., J. IMMUNOL. METH., vol. 62, 1983, pages 1 - 13
LOGANZO ET AL., CANCER RESEARCH, vol. 63, 15 April 2003 (2003-04-15), pages 1838 - 1845
M. CARRASCOR. BROWN, J. ORG. CHEM., vol. 68, 2003, pages 8853 - 8858
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MAHAL, L. K ET AL., SCIENCE, vol. 276, 1997, pages 1125 - 1128
MANGOLD ET AL., MUTATION RES, vol. 308, 1994, pages 33
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
MATEO ET AL., IMMUNOTECHNOL, vol. 3, no. 1, 1997, pages 71 - 81
MATSOUKAS ET AL.: "In vivo incorporation of Unnatural Amino Acids", J. MED. CHEM., vol. 38, 1995, pages 4660 - 4669
MODJTAHEDI ET AL., BR. J. CANCER, vol. 67, no. 2, 1993, pages 247 - 53
MODJTAHEDI ET AL., BR. J. CANCER, vol. 73, no. 2, 1996, pages 228 - 35
MODJTAHEDI ET AL., INT. J. CANCER, vol. 105, no. 2, 2003, pages 273 - 80
MODJTAHEDI ET AL., J. CELL. BIOPHYS., vol. 22, no. 1-3, 1993, pages 129 - 46
MURTHY ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 252, no. 2, 1987, pages 549 - 60
NOLAN, OR. O'KENNEDY, BIOCHIM BIOPHYS ACTA, vol. 1040, no. 1, 1 August 1990 (1990-08-01), pages 1 - 11
PATERSON, D. M ET AL.: "Finding the Right (Bioorthogonal) Chemistry", ACS CHEM BIOL, vol. 9, 2014, pages 592 - 605
PRESTA, CURR. OP. STRUCT. BIOL, vol. 2, 1992, pages 593 - 596
QUEEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 86, 1989, pages 10029 - 10033
RADER ET AL., PROC. NAT. ACAD. SCI. U.S.A., vol. 95, 1998, pages 8910 - 8915
RAMIL, C.PLIN, Q: "Bioorthogonal chemistry: strategies and recent developments", CHEM COMMUN, vol. 49, 2013, pages 11007 - 11022
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
RODECK ET AL., J. CELL. BIOCHEM, vol. 35, no. 4, 1987, pages 315 - 20
RODRIGUES ET AL., CHEMISTRY BIOLOGY, vol. 2, 1995, pages 223
ROSENTHAL, G. ET AL., LIFE SCI, vol. 60, 1997, pages 1635 - 1641
ROSTOVTSEV ET AL., ANGEW. CHEM. INT. ED., vol. 41, 2002, pages 2596 - 2599
SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
SHAO, J.TAM, J. P, J. AM. CHEM. SOC., vol. 117, no. 14, 1995, pages 3893 - 3899
STEINBERGER ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 36073 - 36078
STORM ET AL., J. AMER. CHEM. SOC, vol. 94, 1972, pages 5815
SUBASINGHE ET AL.: "Quisqualic acid analogues: synthesis of beta-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized site", J. MED. CHEM., vol. 35, 1992, pages 4602 - 7
TALPIR ET AL., TETRAHEDRON LETTERS, vol. 35, no. 25, 1994, pages 4453 - 4456
TORNOE, C. W ET AL., J. ORG. CHEM., vol. 67, 2002, pages 3057 - 3064
WADE D, CHEM. BIOL. INTERACT., vol. 117, 1999, pages 191
WINTERMILSTEIN, NATURE, vol. 349, 1991, pages 1069 - 1109
WOLFF, A C ET AL., J CLIN ONCOL, vol. 31, no. 31, 1 November 2013 (2013-11-01), pages 3997 - 4013
YIN ET AL., MABS, vol. 4, 2012, pages 217 - 225
ZELLO ET AL., METABOLISM, vol. 43, 1994, pages 487

Similar Documents

Publication Publication Date Title
US20240139285A1 (en) Immunomodulator antibody drug conjugates and uses thereof
US12534465B2 (en) 5H-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
US20240091365A1 (en) Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
US20220259202A1 (en) 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
US12144869B2 (en) Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
WO2025080711A1 (fr) Conjugués médicament-anticorps à double charge utile
WO2024015229A1 (fr) Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques
US20250122306A1 (en) Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2026080688A1 (fr) Conjugués anticorps-médicament à charge utile à double mécanisme d'action
WO2022103983A9 (fr) Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation
WO2026080697A1 (fr) Conjugués d'anticorps à rapports élevés charge utile/anticorps, compositions les comprenant, et leurs procédés d'utilisation
WO2026080692A1 (fr) Charges utiles à lieur bêta-glucuronide ramifié, conjugués protéiques associés et procédés associés
WO2026043823A2 (fr) Anticorps comprenant des résidus d'acides aminés non naturels spécifiques à un site, leurs procédés de préparation et leurs utilisations